The report on Asia-Pacific diabetes
drug therapy market provides qualitative and quantitative analysis for the
period of 2015 to 2023. According to report the Asia-Pacific diabetes drug
therapy market is expected to grow at a CAGR between 10.0% and 10.5% over the
forecast period of 2017 – 2023. The Asia-Pacific market for diabetes drug
therapy was valued at USD 9.9 billion in 2015 and is expected to reach around
USD 19.2 billion by 2023.
Figure: Asia-Pacific Diabetes Drug Therapy Market by Value 2015 – 2023
Market Insights:
The report identified that
Asia-Pacific diabetes drug therapy is driven by factors such as growing number
of diabetes population, large number of drugs under pipeline, and, need for new
treatments with improved efficacy and launch of new generation of products for
the treatment. While the restraining factors include cost restrains in the developing
regions, and, Lack of awareness, and, less variability in products. Further,
the report identifies the opportunities in the world market as rise in
healthcare expenditure in the developing countries, such as India and China.
Diabetes is group of metabolic
disorder, often referred as diabetes mellitus, results in high blood glucose
levels. Body cells use glucose as a source of energy and insulin is important
for the cells to absorb this glucose. When the body cells loose the capacity to
respond to the insulin or body is not capable of producing sufficient insulin,
it leads to an increase in blood glucose levels in the body. This condition is
referred to as diabetes. Depending on the cause of development, it is divided
into three types, which includes type 1 diabetes (body loses the capacity of
producing sufficient insulin), type 2 diabetes (most common and body cells do
not respond to insulin) and gestational diabetes (occurs in pregnant women).
Among these, type 2 diabetes is the most common type and affects over 90% of
the global diabetic patients.
Segments Covered
The report on Asia-Pacific diabetes
drug therapy market covers type segments. The type segment includes insulin,
biguanides, meglitinides, sulfonylureas, inhibitors, and, others.
Geographic Coverage and Analysis:
The report provides analysis
covering countries such as China, Japan, India, and Rest of the APAC. In this
section the key trends and market size for each country is provided over the
period of 2015 – 2023.
According to the Asian diabetes
prevention organization, below are the some of the key facts and figures
related to Asia-Pacific diabetes population:
·
60% of global diabetic population lives in Asia
·
9 million adults have diabetes in China, which
represents 11.6% of adult population in the country
·
1 million adults live with diabetes in India
·
By 2030, it is estimated that both China and
India combined will have almost half a billion diabetics
·
Asians have a higher percentage of body fat at
the same BMI as whites
·
Almost 1 in 3 cigarettes manufactured around the
globe is smoked in China
The Asia-Pacific diabetes drug
therapy market includes a wide range of drug therapies used by healthcare
professionals and patients to treat their blood glucose levels. The key drivers
of this market growth include growing number of diabetes population, rise in
base of geriatric population, large number of drugs under pipeline, need for
new treatments with improved efficacy and launch of new generation of products
for the treatment. Growing demand from emerging markets and supportive
government initiatives are also been among foremost factors driving demand of
diabetes drugs market.
Companies Profiled:
The report provides profiles of
the companies in the Asia-Pacific diabetes drug therapy market such as, Abbott
Laboratories, Mannkind Corporation, Bristol Myers Squibb, Medtronic,
AstraZeneca, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Sanofi, Novo
Nordisk, and Novartis International AG.
Report Highlights:
The report provides deep insights
on demand forecasts, market trends and micro and macro indicators. In addition,
this report provides insights on the factors that are driving and restraining
the Asia-Pacific diabetes drug therapy market. Moreover, IGR-Growth Matrix
analysis given in the report brings an insight on the investment areas that
existing or new market players can consider. The report provides insights into
the market using analytical tools such as Porter’s five forces analysis and DRO
analysis of diabetes drug therapy market.
Moreover, the study highlights
current market trends and provides forecast from 2016 to 2023. We also have
highlighted future trends in the diabetes drug therapy market that will impact
the demand during the forecast period. Moreover, the competitive analysis given
in each regional market brings an insight on the market share of the leading
players. Additionally, the analysis highlights rise and fall in the market
shares of the key players in the market. This report will help manufacturers,
suppliers and distributors of the diabetes drug therapy market to understand
the present and future trends in this market and formulate their strategies
accordingly.
Please Choose One of them.